Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled

Primary tabs

field_vote: 
Average: 8 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Therapeutic Substance(s): 

Zhong Xi Yi Jie He Xue Bao. 2008 Feb;6(2):134-8.

[Artesunate
combined with vinorelbine plus cisplatin in treatment of advanced
non-small cell lung cancer: a randomized controlled trial]

Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, Xia XH, Li DQ.
Department of Respiratory Medicine, Dongguan Kuanghua Hospital, Dongguan, Guangdong Province, China.
OBJECTIVE:
To our knowledge, there has been no clinical report of artesunate in
the treatment of lung cancer. This study was designed to compare the
efficacy and toxicity of artesunate combined with NP (a chemotherapy
regimen of vinorelbine and cisplatin) and NP alone in the treatment of
advanced non-small cell lung cancer (NSCLC).
METHODS: One hundred and
twenty cases of advanced NSCLC were randomly divided into simple
chemotherapy group (control group, n=60) and combined artesunare with
chemotherapy group (trial group, n=60). Patients in the control group
were treated with NP regimen, including vinorelbine (25 mg/m(2),
once-a-day intravenous injection, at the 1st and 8th day) and cisplatin
(25 mg/m(2), once-a day intravenous drip, at the 2nd to 4th day).
Patients in the trial group were treated with the basal therapy NP (in
the same method and doses as control group) and artesunate (120 mg,
once-a-day intravenous injection, from the 1st day to 8th day, for 8
days). At least two 21-day-cycles of treatment were performed. The
short-term survival rate, disease controlled rate (DCR), time to
progression (TTP), mean survival time (MST) and 1-year survival rate
were analyzed as the primary end points, and the toxicity and safety
were estimated.
RESULTS: There were no significant differences in the
short-term survival rate, MST and 1-year survival rate between the
trial group and the control group, which were 45.1% and 34.5%, 44 weeks
and 45 weeks, 45.1% and 32.7%, respectively (P>0.05). The DCR of the
trial group (88.2%) was significantly higher than that of the control
group (72.7%) (P<0.05), and the trial group's TTP (24 weeks) was
significantly longer than that of the control group (20 weeks)
(P<0.05). No significant difference was found in toxicity between
the two groups, such as myelosuppression and digestion reaction
(P>0.05).
CONCLUSION: Artesunate can be used in the treatment of
NSCLC. Artesunate combined with NP can elevate the short-term survival
rate and prolong the TTP of patients with advanced NSCLC without extra
side effects.